Chronic rhinosinusitis with nasal polyposis: the role of personalized and integrated medicine

Main Article Content

Desiderio Passali
Luisa Maria Bellussi
Valerio Damiani
Maria Angela Tosca
Gaetano Motta
Giorgio Ciprandi

Keywords

chronic rhinosinusitis, nasal polyposis, biological agents, corticosteroids, enoxolone, mannitol

Abstract

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a frequent disorder. From a clinical and an immunopathological point of view, different phenotypes and endotypes have been identified. The frequent comorbidity with asthma allowed to pave the way to the use of biological agents for the treatment of CRSwNP. Biological agents are targeted to antagonize IgE, interleukin (IL) 4, IL-5, and IL-13 at present. However, a correct and appropriate workup is mandatory, mainly concerning the exact definition of the specific pheno-endotype. The preliminary outcomes are promising, even though there is a need for well-established indications, criteria of responsiveness, duration, and safety. On the other hand, this personalized medicine could be fruitfully integrated with gold-standard medications, such as intranasal corticosteroids. As CRSwNP is a chronic disorder, treatment should be long-lasting, so complementary anti-inflammatory treatments could be opportunely integrated and/or alternated to steroids.

a

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...
Abstract 82 | PDF Downloads 45

References

1) Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A, et al. Chronic rhinosinusitis in Europe—an underestimated disease. A GA(2)LEN study. Allergy 2011;66:1216-23
2) Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol 2015; 136:1431-40
3) Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012;50:1–12
4) Orlandi RR, Kingdom TT, Hwang PH, et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol. 2016;6 Suppl 1:S22-209
5) Lund VJ, Mackay IS. Staging in rhinosinusitis. Rhinology 1993;31:183-4
6) Bachert C, Gevaert P, Holtappels G, Johansson SG, van Cauwenberge P. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol 2001;107:607-14.
7) Mygind N, Dahl R, Bachert C. Nasal polyposis, eosinophil dominated inflammation, and allergy. Thorax 2000;55(suppl 2): S79-83
8) Gevaert P, Bachert C, Holtappels G, Novo CP, Van der Heyden J, Fransen L, et al. Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy 2003;58:371-9
9) Patou J, Holtappels G, Affleck K, Gevaert P, Perez-Novo C, Van Cauwenberge P, et al. Enhanced release of IgE-dependent early phase mediators from nasal polyp tissue. J Inflamm (Lond) 2009;6:11
10) Timmerman L. What's in a Name? A Lot, When It Comes to 'Precision Medicine. Xconomy, 4 February 2013
11) Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: moving toward precision medicine. J Allergy Clin Immunol 2019;144:1-12
12) Guilleminault L, Ouksel H, Belleguic C, Le Guen Y, Germaud P, Desfleurs E, et al. Personalised medicine in asthma: from curative to preventive medicine. Eur Respir Rev. 2017;26(143)
13) Bachert C, Vignola AM, Gevaert P, Leynaert B, Van Cauwenberge P, Bousquet J. Allergic rhinitis, rhinosinusitis, and asthma: one airway disease. Immunol Allergy Clin North Am 2004;24:19-43.
14) Global Initiative for Asthma. GINA guidelines. Global Strategy for Asthma Management and Prevention. 2019. Available at: htpp://www.ginasthma.org/. Last accessed on September 2019
15) GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5:691-706
16) Ciprandi G, Cirillo I. The lower airway pathology of Rhinitis. Update Review J Allergy Clin Immunol 2006; 118:1105-1109
17) Tay TR, Hew M. Comorbid “treatable traits” in difficult asthma. Current evidence and clinical evaluation. Allergy 2018;73:1369-82
18) Lin DC, Chandra RK, Tan BK, Zirkle W, Conley DR, Grammer LC, et al. Association between severity of asthma and degree of chronic rhinosinusitis. Am J Rhinol Allergy 2011;25:205-8
19) Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation, and treatment of severe asthma. Eur Respir J 2014;43:343-73
20) Casale TB, Israel E. Biologics, clinical context, and the asthmas. J Allergy Clin Immunol Pract 2019;7:1437-9
21) Gurrola J II, Borish L. Chronic rhinosinusitis: endotypes, biomarkers, and treatment response. J Allergy Clin Immunol 2017;140:499-508
22) Tsetsos N, Goudakos JK, Daskalakis D, Konstantinidis I, Markou K. Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review. Rhinology. 2018;56:11-21
23) Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013;131:110-6
24) Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 2016;315:469-479
25) Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: a randomized trial. J Allergy Clin Immunol. 2017;140:1024-1031.e14
26) Bidder T, Sahota J, Rennie C, Lund VJ, Robinson DS, Kariyawasam HH. Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real-life study. Rhinology. 2018;56:42-45
27) Fokkens WJ, Bachert C, Bernal-Sprekelsen M, et al. Rhinology future debates, a EUFOREA report. Rhinology. 2017;55: 298-304
28) Hellings PW, Akdis CA, Bachert C, et al. EUFOREA rhinology research forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis. Rhinology. 2017;55:202-210
29) Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 2019 (in press)
30) Vlastos I, Gkouskou K, Doulaptsi M, Karatzanis A, Prokopakis EP. Precision medicine in rhinosinusitis. Curr Allergy Asthma rep 2019;19:12
31) Dennis SK, Lam K, Luong A. A review of classification schemes for chronic rhinosinusitis with nasal polyposis endotypes. Laryngoscope Investig Otolaryngol. 2016;1:130–4
32) Liu JX, Liao B, Yu QH, Wang H, Liu YB, Guo CL, et al. IL-37-Mex3B-TLR3 axis in epithelial cells in eosinophilic chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019 (in press)
33) Ricciardolo F, Sorbello V, Folino A, Gallo F, Massaglia GM, Favatà G, et al. Identification of IL-17F/frequent exacerbator endotype in asthma. J Allergy Clin Immunol 2017;140(2):395-406
34) Bachert C, Akdis CA. Phenotypes and emerging endotypes of chronic rhinosinusitis. J Allergy Clin Immunol Pract 2016;4: 621–8
35) Sommer DD, Rotenberg BW, Sowerby LJ, Lee JM, Janjua A, Witterick IJ, et al. A novel treatment adjunct for aspirin-exacerbated respiratory disease: the low-salicylate diet: a multicenter randomized control crossover trial. Int Forum Allergy Rhinol. 2016;6:385–91
36) De Greve G, Hellings PW, Fokkens WJ, Pugin B. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy 2017;7:22
37) Tomassen P, Vandeplas G, van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol 2016;137:1449–1456 e4
38) White AA, Doherty TA. Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis. Am J Rhinol Allergy. 2018;32:7-11
39) de Campos L, Galvão CES, Mairena EC, Voegels R, Kalil J, Castro FM, et al. Increased gene expression of inflammatory markers in nasal turbinate of patients with persistent allergic rhinitis and chronic obstruction. Eur Arch Otorhinolaryngol. 2019 (in press)
40) Soler ZM, Hyer JM, Ramakrishnan V, Smith TL, Mace J, Rudmik L, et al. Identification of chronic rhinosinusitis phenotypes using cluster analysis. Int Forum Allergy Rhinol 2015;5:399–407
41) Doulaptsi M, Prokopakis E, Seys S, Pugin B, Steelant B, Hellings P. Visual analogue scale for sino-nasal symptoms severity correlates with sino-nasal outcome test 22: paving the way for a simple outcome tool of CRS burden. Clin Transl Allergy 2018;8:32
42) Bachert C, Zhang N, Hellings PW, Bousquet J. Endotype-driven care pathways in patients with chronic rhinosinusitis. J Allergy Clin Immunol 2018;141:1543– 51
43) Divekar R, Hagan J, Rank M, Park M, Volcheck G, O'Brien E, et al. Diagnostic utility of urinary LTE4 in asthma, allergic rhinitis, chronic rhinosinusitis, nasal polyps, and aspirin sensitivity. J Allergy Clin Immunol Pract 2016;4:665–70
44) Baines KJ, Pavord ID, Gibson PG. The role of biomarkers in the management of airways disease. Int J Tuberc Lung Dis. 2014;18:1264–8
45) Kim DW, Cho SH. Emerging endotypes of chronic rhinosinusitis and its application to precision medicine. Allergy Asthma Immunol Res 2017;9:299–306
46) Benninger MS, Sindwani R, Holy CE, Hopkins C. Early versus delayed endoscopic sinus surgery in patients with chronic rhinosinusitis: impact on health care utilization. Otolaryngol Head Neck Surg 2015;152:546–52
47) Hopkins C, Rimmer J, Lund VJ. Does time to endoscopic sinus surgery impact outcomes in chronic Rhinosinusitis? Prospective findings from the National Comparative Audit of Surgery for Nasal Polyposis and Chronic Rhinosinusitis. Rhinology 2015;53:10–7
48) Avdeeva K, Fokkens W. Precision Medicine in Chronic Rhinosinusitis with Nasal Polyps. Curr Allergy Asthma Rep 2018;18:25
49) Pinto JM, Mehta N, Di Tineo M, et al. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 2010;48:318-24
50) Vennera M, Picado C, Mullol J, et al. Efficacy of omalizumab in the treatment of nasal polyps. Thorax 2011;66:824-5
51) Bidder, Sahota J, Rennie C, Lund VJ, Robinson DS, Kariyawasam HH. Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together – a real-life study. Rhinology 2018;56:42-5
52) Pillal P, Chan YC, Wu SY, et al. Omalizumab reduces bronchial mucosa IgE and improves lung function in non-atopic asthma. Eur Respir J 2016;48:1593-1601
53) Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198-207
54) Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006;118:1133-41
55) Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011;128:989-95, e1-8
56) Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol 2017;140:1024-31
57) Weinstein SF, Katial RK, Bardin P, Korn S, McDonald M, Garin M, et al. Effects of Reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract 2019;7.589-96
58) Ghazi A. Benralizumab—a humanized MAb to IL-5Ra with enhanced antibody-dependent cell-mediated cytotoxicity—a novel approach for the treatment of asthma. Expert Opin Biol Ther 2011;12:113–118
59) Tsurumaki H, Matsuyama T, Ezawa K, Koga Y, Yatomi M, Aoki-Saito H, et al. Rapid effect of Benralizumab for hypereosinophilia in a case of severe asthma with eosinophilic chronic rhinosinusitis. Medicine (Kaunas) 2019;3:55
60) Kim H, Ellis AK, Fischer D, et al. Asthma biomarkers in the age of biologics. Allergy Asthma Clin Immunol 2017;13:48
61) Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 2016;315:469‐479
62) Jonstam K, Swanson BN, Mannent LP, Cardel LO, Tian N, Wang Y, et alò. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy 2019;74:743-52
63) Kartush AG, Schumacher JK, Shah R, Patadia MO. Biologic agents for the treatment of chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy 2019;33:203-11
64) Ciprandi G, Tosca MA, Silvestri M, Ricciardolo FLM. Inflammatory biomarkers for asthma endotyping and consequent personalized therapy. Expert Review Clin Immunol 2017;13:715-21
65) Ellis AK, Tenn MW. Advances in rhinitis: Models and mechanisms. Ann Allergy Asthma Immunol 2018;121:61-64
66) Ciprandi G, Varricchio A, Tajana G, La Mantia I, Tommasino C. Peripheral eosinophils correlate with nasal eosinophils in patients with rhinitis. J Invest Allergol Clin Immunol 2018;28:428-30
67) Ciprandi G, Silvestri M. Standardization of the nasal cytology in the work-up of allergic rhinitis. Ann All Asthma Immunol 2019;123:213-6
68) Ricciardolo F, Sorbello V, Ciprandi G. FeNO as biomarker for asthma phenotyping and management. Allergy Asthma Proc 2015;36:1-8
69) Gelardi M, Abbatista G, Quaranta VN, Quaranta N, Seccia V, Buttafava S, et al. Standardization procedure for the nasal nitric oxide measurement method using Niox MINO® and the tidal-breathing technique with velum-closure. J Biol Res 2016;30:853-858.
70) Roth-Walter F, Adcock IM, Benito-Villalvilla C, Bianchini R, Bjermer L, Caramori G, et al. Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: an EACCI Taskforce on immunopharmacology position paper. Allergy 2019;74:432-448
71) Passali D, Spinosi MC, Crisanti A, Bellussi LM. Mometasone furoate nasal spray: a systematic review. Multidisc Respir Medicine 2016;11:18
72) Ciprandi G, Varricchio A. The relevance of the mometasone furoate nasal spray in clinical practice. J Biol Reg Hom Ag 2018;32:239-42
73) Ciprandi G, Tosca MA. Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge. Ann Allergy Asthma Immunol 2001;86:433-8
74) Ikeda K, Ito R, Homma H, Ono N, Okada H, Kidokoro Y, et al. Postoperative management of eosinophilic chronic rhinosinusitis with nasal polyps: impact of high-dose corticosteroid nasal spray. Int Arch Otorhinolaryngol 2019;23:101-3
75) Akkaş H, Aydın E, Türkoğlu Babakurban S, Yurtcu E, Yılmaz Özbek Ö. Effect of mometasone furoate nasal spray on the DNA of nasal mucosal cells. Turk J Med Sci. 2018;48:339-345
76) Ocak E, Kocaoz D, Acar B. How can we improve medical adherence to intranasal corticosteroids in children? Int J Pediatr Otorhinolaryngol. 2017;100:194-197
77) Alhussien AH, Alhedaithy RA, Alsaleh SA. Safety of intranasal corticosteroid sprays during pregnancy: an updated review. Eur Arch Otorhinolaryngol. 2018;275:325-333
78) Chung WT, Lee SH, Kim JD, Sung NS, Hwang B, Lee SY, et al. Effect of the extracts from Glycyrrhiza uralensis Fisch in the growth cgìharacteristics of human cell lines: anti-tumor and immune activation activities. Cytotechnology 2001;37:55-64
79) Wang LQ, He Y, Wan HF, Zhou HF, Yang JH, Wan HT. Protective mechanisms of hypaconitine and glycyrrhetinic acid compatibility in oxygen and glucose deprivation injury. J Zhejiang Univ Sci B 2017;18:586-96
80) Cavone L, Cuppari C, Mansi S, Grasso L, Arrigo T, Calamai L, et al. Increase in the level of proinflammatory cytokine HMGB1 in nasal fluids of patients with rhinitis and its sequestration by glycyrrhizin induces eosinophil cell death. Clin Exp Otorhinolaryngol 2025;8:123-8
81) Passali D, Capopello C, Passali GC, Cingi C, Sarafoleanu C, Bellussi LM. Nasal mucociliary transport time alteration: efficacy of 18 B glycyrrhetinic acid. Multidiscipl Respir Med 2017;12:29
82) Damiani V, Camaioni A, Viti C, Scirò AS, Morpurgo G, Gregori D. A single-center, a before-after study of the short- and long-term efficacy of Narivent in the treatment of nasal congestion. J Int Med Res 2012;40:1931-41
83) Mansi N, D’Agostino G, Scirè AS, Morpurgo G, Gregori D, Gulati A, et al. Allergic rhinitis in children: a randomized clinical trial targeted at symptoms. Indian J Otolaryngol Head Neck Surg 2014;66:386-93

Most read articles by the same author(s)

1 2 > >>